As Epigenetics and Therapeutics in Immuno-Oncology refer, Cheng laboratory aims at identifying the cause (etio in Greek) and solution of cancer therapeutic resistance. On the one hand, we apply the cutting-edge single-cell multi-omics and AI innovation to understand tumor adaptation to immune-checkpoint blockade (ICB) and uncover the epigenetic and transcriptional programs underlying immunotherapeutic resistance. On the other hand, we develop effective and durable combination immunotherapies for clinical translation. A prime example is a novel class I HDAC-targeted epigenetic immunotherapy, which has secured governmental and industrial support to commence a Phase-II clinical trial for hepatocellular carcinoma patients resisting to ICB therapy(NCT05873244). Through collaborations with leading experts in the field, our research is expected to have major impact in both basic research and treatment for this fatal cancer.

Prof. CHENG Sze Lok Alfred 鄭詩樂教授

Our Research

Our team of passionate researchers focuses on understanding the epigenetic and transcriptional programs underlying immunotherapeutic resistance.

Join us as we embark on this crucial mission to revolutionize cancer treatment and make a meaningful impact on patient outcomes.

News

Stay informed as we share groundbreaking research, events, noteworthy publications, and more taking place in our lab.

Our Team

We foster an enriching environment that values teamwork, curiosity, and creativity. Our mentorship style is designed to empower individuals, providing guidance and support as they navigate their scientific journeys.

Together, we cultivate an inclusive and stimulating atmosphere that nurtures personal and professional development, ensuring that every member of our team thrives.